Claritev Returns to Revenue Growth in 2025, Eyes Profitability in 2026
Event summary
- Claritev reported $965.4 million in full-year 2025 revenue, up 3.7% from 2024.
- Net loss narrowed to $284.3 million in 2025 from $1.65 billion in 2024.
- Company processed $179.8 billion in claim charges in 2025, identifying $25 billion in potential medical cost savings.
- Board approved a five-year, $75 million share repurchase program starting January 2026.
The big picture
Claritev's return to revenue growth in 2025 marks a strategic turnaround after years of financial challenges. The company's focus on operational execution and cost savings aligns with broader industry trends toward healthcare affordability and transparency. With a clear path to profitability in 2026, Claritev aims to position itself as a leader in data-driven healthcare solutions.
What we're watching
- Profitability Timeline
- Whether Claritev can sustain its path to positive free cash flow in 2026 as projected.
- M&A Strategy
- How the company will allocate capital for value-creating acquisitions under its new repurchase program.
- Market Expansion
- The pace at which Claritev can expand into new vertical markets while maintaining operational efficiency.
Related topics